A P Barbour1, E T Walpole2, G T Mai2, E H Barnes3, D I Watson4, S P Ackland5, J M Martin5, M Burge6, R Finch7, C S Karapetis4, J Shannon8, L M Nott9, S Varma10, G Marx11, G L Falk11, V Gebski3, M Oostendorp3, K Wilson3, J Thomas12, G Lampe2, J R Zalcberg13, J Simes3, B M Smithers14. 1. Divisions of Surgery and Cancer Services, Princess Alexandra Hospital, Brisbane, Australia; Faculty of Medicine, The University of Queensland, Brisbane, Australia. Electronic address: a.barbour@uq.edu.au. 2. Divisions of Surgery and Cancer Services, Princess Alexandra Hospital, Brisbane, Australia. 3. National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia. 4. Department of Surgery, Flinders Medical Centre, Adelaide, Australia; School of Medicine, Flinders University, Adelaide, Australia. 5. School of Medicine and Public Health, University of Newcastle, Newcastle, Australia. 6. Faculty of Medicine, The University of Queensland, Brisbane, Australia; Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia. 7. Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia. 8. Nepean Cancer Centre, Nepean Hospital, Sydney, Australia. 9. Medical Oncology, Royal Hobart Hospital, Hobart, Australia. 10. Cancer Services, Townsville Hospital, Townsville, Australia. 11. Clinical Trials Unit, Sydney Adventist Hospital, Sydney, Australia. 12. Divisions of Surgery and Cancer Services, Princess Alexandra Hospital, Brisbane, Australia; Clinical Trials, Mater Research Institute, Brisbane, Australia. 13. School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia. 14. Divisions of Surgery and Cancer Services, Princess Alexandra Hospital, Brisbane, Australia; Faculty of Medicine, The University of Queensland, Brisbane, Australia.
Abstract
BACKGROUND: Patients with oesophageal/gastro-oesophageal junction adenocarcinoma (EAC) not showing early metabolic response (EMR) to chemotherapy have poorer survival and histological response rates <5%. We investigated whether tailoring neoadjuvant therapy can improve outcomes in these patients. PATIENTS AND METHODS: Patients with resectable EAC were enrolled and randomised into two single-arm, multicentre phase II trials. After induction cisplatin and 5-fluorouracil (CF), all were assessed by day 15 positron emission tomography (PET). Patients with an EMR [maximum standardised uptake values (SUVmax) ≥35% reduction from baseline to day 15 PET] received a second CF cycle then oesophagectomy. Non-responders were randomised 1 : 1 to two cycles of CF and docetaxel (DCF, n = 31) or DCF + 45 Gy radiotherapy (DCFRT, n = 35) then oesophagectomy. The primary end point was major histological response (<10% residual tumour) in the oesophagectomy specimen; secondary end points were overall survival (OS), progression-free survival (PFS), and locoregional recurrence (LR). RESULTS: Of 124 patients recruited, major histological response was achieved in 3/45 (7%) with EMR, 6/30 (20%) DCF, and 22/35 (63%) DCFRT patients. Grade 3/4 toxicities occurred in 12/45 (27%) EMR (CF), 13/31 (42%) DCF, and 25/35 (71%) DCFRT patients. No treatment-related deaths occurred. LR by 3 years was seen in 5/45 (11%) EMR, 10/31 (32%) DCF, and 4/35 (11%) DCFRT patients. PFS [95% confidence interval (CI)] at 36 months was 47% (31% to 61%) for EMR, 29% (15% to 45%) for DCF, and 46% (29% to 61%) for DCFRT patients. OS (95% CI) at 60 months was 53% (37% to 67%) for EMR, 31% (16% to 48%) for DCF, and 46% (29% to 61%) for DCFRT patients. CONCLUSIONS: EMR is associated with favourable OS, PFS, and low LR. For non-responders, the addition of docetaxel augmented histological response rates, but OS, PFS, and LR remained inferior compared with responders. DCFRT improved histological response and PFS/LR outcomes, matching the EMR group. Early PET/CT has the potential to tailor therapy for patients not showing an early response to chemotherapy. TRIAL REGISTRATION: ACTRN12609000665235. Crown
BACKGROUND: Patients with oesophageal/gastro-oesophageal junction adenocarcinoma (EAC) not showing early metabolic response (EMR) to chemotherapy have poorer survival and histological response rates <5%. We investigated whether tailoring neoadjuvant therapy can improve outcomes in these patients. PATIENTS AND METHODS: Patients with resectable EAC were enrolled and randomised into two single-arm, multicentre phase II trials. After induction cisplatin and 5-fluorouracil (CF), all were assessed by day 15 positron emission tomography (PET). Patients with an EMR [maximum standardised uptake values (SUVmax) ≥35% reduction from baseline to day 15 PET] received a second CF cycle then oesophagectomy. Non-responders were randomised 1 : 1 to two cycles of CF and docetaxel (DCF, n = 31) or DCF + 45 Gy radiotherapy (DCFRT, n = 35) then oesophagectomy. The primary end point was major histological response (<10% residual tumour) in the oesophagectomy specimen; secondary end points were overall survival (OS), progression-free survival (PFS), and locoregional recurrence (LR). RESULTS: Of 124 patients recruited, major histological response was achieved in 3/45 (7%) with EMR, 6/30 (20%) DCF, and 22/35 (63%) DCFRT patients. Grade 3/4 toxicities occurred in 12/45 (27%) EMR (CF), 13/31 (42%) DCF, and 25/35 (71%) DCFRT patients. No treatment-related deaths occurred. LR by 3 years was seen in 5/45 (11%) EMR, 10/31 (32%) DCF, and 4/35 (11%) DCFRT patients. PFS [95% confidence interval (CI)] at 36 months was 47% (31% to 61%) for EMR, 29% (15% to 45%) for DCF, and 46% (29% to 61%) for DCFRT patients. OS (95% CI) at 60 months was 53% (37% to 67%) for EMR, 31% (16% to 48%) for DCF, and 46% (29% to 61%) for DCFRT patients. CONCLUSIONS: EMR is associated with favourable OS, PFS, and low LR. For non-responders, the addition of docetaxel augmented histological response rates, but OS, PFS, and LR remained inferior compared with responders. DCFRT improved histological response and PFS/LR outcomes, matching the EMR group. Early PET/CT has the potential to tailor therapy for patients not showing an early response to chemotherapy. TRIAL REGISTRATION: ACTRN12609000665235. Crown
Authors: V F Bonazzi; L G Aoude; S Brosda; J M Lonie; K Patel; J J Bradford; L T Koufariotis; S Wood; B Mark Smithers; N Waddell; A P Barbour Journal: ESMO Open Date: 2022-03-23
Authors: M M K Veenstra; B M Smithers; E Visser; D Edholm; S Brosda; J M Thomas; D C Gotley; I G Thomson; B P L Wijnhoven; A P Barbour Journal: BJS Open Date: 2021-01-08
Authors: Radka Obermannova; Iveta Selingerova; Zdenek Rehak; Vaclav Jedlicka; Marek Slavik; Pavel Fabian; Ivo Novotny; Milada Zemanova; Hana Studentova; Peter Grell; Lenka Zdrazilova Dubska; Regina Demlova; Tomas Harustiak; Renata Hejnova; Igor Kiss; Rostislav Vyzula Journal: Ther Adv Med Oncol Date: 2022-01-05 Impact factor: 8.168
Authors: R Mercieca-Bebber; E H Barnes; K Wilson; Z Samoon; E Walpole; T Mai; S Ackland; M Burge; G Dickie; D Watson; J Leung; T Wang; R Bohmer; D Cameron; J Simes; V Gebski; M Smithers; J Thomas; J Zalcberg; A P Barbour Journal: BMC Cancer Date: 2022-03-15 Impact factor: 4.430
Authors: Constantin Lapa; Ursula Nestle; Nathalie L Albert; Christian Baues; Ambros Beer; Andreas Buck; Volker Budach; Rebecca Bütof; Stephanie E Combs; Thorsten Derlin; Matthias Eiber; Wolfgang P Fendler; Christian Furth; Cihan Gani; Eleni Gkika; Anca-L Grosu; Christoph Henkenberens; Harun Ilhan; Steffen Löck; Simone Marnitz-Schulze; Matthias Miederer; Michael Mix; Nils H Nicolay; Maximilian Niyazi; Christoph Pöttgen; Claus M Rödel; Imke Schatka; Sarah M Schwarzenboeck; Andrei S Todica; Wolfgang Weber; Simone Wegen; Thomas Wiegel; Constantinos Zamboglou; Daniel Zips; Klaus Zöphel; Sebastian Zschaeck; Daniela Thorwarth; Esther G C Troost Journal: Strahlenther Onkol Date: 2021-07-14 Impact factor: 3.621
Authors: Harry H Yoon; Fang-Shu Ou; Gamini S Soori; Qian Shi; Dennis A Wigle; Robert P Sticca; Robert Clell Miller; James L Leenstra; Patrick J Peller; Brenda Ginos; Erica Heying; Tsung-Teh Wu; Timothy F Drevyanko; Stephen Ko; Bassam Ibrahim Mattar; Daniel A Nikcevich; Robert J Behrens; Maged F Khalil; George P Kim; Steven R Alberts Journal: Eur J Cancer Date: 2021-04-29 Impact factor: 10.002